Literature DB >> 3192391

Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study.

J D Cowan, S Green, J Lucas, J K Weick, S P Balcerzak, S E Rivkin, C A Coltman, L H Baker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3192391     DOI： 10.1007/bf00175408

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  3 in total

Review 1.  Malignant mesothelioma. Current status and future prospects.

Authors:  J Aisner; P H Wiernik
Journal:  Chest       Date:  1978-10       Impact factor: 9.410

2.  A model for the action of vinblastine in vivo.

Authors:  F A Valeriote; W R Bruce; B E Meeker
Journal:  Biophys J       Date:  1966-03       Impact factor: 4.033

3.  Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.

Authors:  H Y Yap; G R Blumenschein; M J Keating; G N Hortobagyi; C K Tashima; T L Loo
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar
  3 in total
  2 in total

Review 1.  Chemotherapy for malignant pleural mesothelioma: past results and recent developments.

Authors:  S Tomek; S Emri; K Krejcy; C Manegold
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

Review 2.  Programmed cell death, redox imbalance, and cancer therapeutics.

Authors:  Xiaofeng Dai; Danjun Wang; Jianying Zhang
Journal:  Apoptosis       Date:  2021-07-08       Impact factor: 4.677
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.